France Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis

France Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis


$ 3999

France's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $502 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.1% from 2022 to 2030 and will reach $806 Mn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate of the aging population. The market is segmented by Drug class and By distribution channel. Some key players in this market are Salt Med, Adamis Pharmaceuticals Corporation, Almirall, Astellas Pharma, American Hospital of Paris, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, and others.

ID: IN10FRPH410 CATEGORY: Pharmaceuticals GEOGRAPHY: France AUTHOR: Nandini Shah

Buy Now

France Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Executive Summary

France's Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market was valued at $502 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 6.1% from 2022 to 2030 and will reach $806 Mn in 2030. A widespread, preventable, and treatable chronic lung illness that affects both men and women worldwide is a chronic obstructive pulmonary disease (COPD). Airflow into and out of the lungs is restricted as a result of abnormalities in the tiny airways of the lungs. The airways narrow due to a number of factors. Parts of the lung may be destroyed, the airways may be obstructed by mucus, and the lining of the airways may become inflamed and swollen.

The COPD therapeutics market in France is expected to grow at a moderate pace in the coming years, driven by factors such as the increasing prevalence of COPD, growing awareness about the disease, and the launch of new drugs. Currently, bronchodilators and inhaled corticosteroids are the most commonly used medications for COPD treatment in France. Long-acting beta-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are the most commonly prescribed bronchodilators, while inhaled corticosteroids are often used in combination with LAB.

France COPD Therapeutics Market

Market Dynamics

Market Growth Drivers

COPD is a major public health concern in France, with an estimated 3.5 million people affected by the disease. According to a report, the prevalence of COPD in France is expected to increase from 4.9% in 2019 to 5.1% in 2028. This increasing prevalence is expected to drive demand for COPD treatments in the coming years. The COPD therapeutics market in France is expected to be driven by the launch of new drugs. Several major pharmaceutical companies, including GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, and Novartis, are investing heavily in the research and development of new drugs for COPD treatment. This drug is expected to generate significant revenue for the company in the coming years. There is a growing awareness of COPD in France, which is expected to drive demand for COPD treatments.

According to a recent survey by the French National Institute of Health and Medical Research (INSERM), 59% of French people are aware of COPD, compared to 46% in 2005. This increased awareness is expected to lead to earlier diagnosis and treatment of COPD, driving the market growth. The French government is taking steps to address the COPD epidemic, which is expected to drive market growth. For example, the government has launched public awareness campaigns, promoting smoking cessation programs, and providing funding for research on COPD prevention and treatment. In addition, the government has introduced regulations to limit smoking in public places, which is expected to reduce the prevalence of COPD in the long term.

Market Restraints

The French healthcare system is highly regulated, and the government sets prices for many drugs. This can create pricing pressures for pharmaceutical companies operating in the COPD therapeutics market in France. Additionally, the French government has been working to reduce healthcare costs, which may result in further pricing pressures on drugs used to treat COPD. Many of the drugs used to treat COPD are nearing the end of their patent protection. This means that pharmaceutical companies may face increased competition from generic versions of these drugs, which can lead to lower revenues.

The approval process for new drugs in France can be complex and lengthy, which can delay the launch of new drugs and increase development costs. This can be a challenge for pharmaceutical companies operating in the COPD therapeutics market in France. While the French healthcare system provides universal coverage, not all COPD treatments are fully reimbursed. This can limit patient access to some treatments and may impact the overall demand for COPD therapeutics in the country. While the French government has taken steps to reduce smoking rates, France still has a relatively high smoking rate compared to other European countries. This can contribute to the high prevalence of COPD in the country and may limit the effectiveness of public health campaigns to reduce COPD rates.

Competitive Landscape

Key Players

  • Abbott Laboratories
  • Salt Med
  • Adamis Pharmaceuticals Corporation
  • American Hospital of Paris
  • Astellas Pharma
  • AstraZeneca
  • Boehringer Ingelheim Pharmaceuticals
  • Novartis
  • Pfizer

Healthcare Policies and Regulatory Landscape

France has a universal healthcare system known as the French Health Insurance (Assurance Maladie), which provides access to medical services and treatments to all residents, regardless of their income or health status. The system is financed through contributions from employers, employees, and the government, as well as through taxes. The French government is actively involved in healthcare policy in France and plays a major role in regulating the healthcare industry. The government sets prices for many drugs and also regulates the approval process for new drugs.

In terms of healthcare policy specific to the COPD therapeutics market, the French government has taken several initiatives to address the COPD epidemic. For example, the government has launched public awareness campaigns to increase knowledge and understanding of COPD and has introduced regulations to limit smoking in public places. Additionally, the government provides funding for research on COPD prevention and treatment. The French healthcare system also provides reimbursement for many COPD treatments, although not all treatments are fully reimbursed. The government regulates the prices of drugs used to treat COPD, which can create pricing pressures for pharmaceutical companies operating in the market.

Reimbursement Scenario

In France, the healthcare system provides reimbursement for many COPD treatments, although not all treatments are fully reimbursed. The level of reimbursement depends on several factors, including the type of treatment, the patient's medical condition, and the severity of the disease. The reimbursement process is regulated by the French National Health Insurance Fund (CNAM), which determines the reimbursement rate for each drug based on its therapeutic value and its price. The reimbursement rate can vary from 15% to 100% of the drug's cost, depending on its classification.

Drugs used to treat COPD are generally reimbursed, although the reimbursement rate may vary depending on the specific drug and the patient's condition. For example, bronchodilators, which are commonly used to treat COPD, are generally fully reimbursed, while some other treatments, such as pulmonary rehabilitation programs, may only be partially reimbursed.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

France Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Segmentation

By Drug Class

Bronchodilators: Bronchodilators are medications that help to relax the muscles around the airways, making it easier to breathe. These can be further classified as short-acting or long-acting bronchodilators.

Corticosteroids: Corticosteroids are anti-inflammatory medications that can help reduce swelling and inflammation in the airways. These can be used alone or in combination with bronchodilators.

Combination Therapies: Combination therapies combine bronchodilators and corticosteroids in a single medication. These are often used for patients with more severe COPD.

Phosphodiesterase-4 Inhibitors: Phosphodiesterase-4 inhibitors are medications that help to reduce inflammation and improve airflow in the lungs.

Others: Other medications that may be used to treat COPD include mucolytics, oxygen therapy, and vaccines for influenza and pneumococcal disease.

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Insights10 will provide you with the reports within 10 key parameters which are:

  1. Market Overview
  2. Market Growth Drivers & Restraints
  3. Epidemiology of Disease Type
  4. Market Segmentation
  5. Market Share
  6. Competitive Landscape
  7. Key Company Profiles
  8. Healthcare Policies & Regulatory Framework
  9. Reimbursement Scenario
  10. Factors Driving Future Growth

Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.

 

Stage I: Market Data Collection

Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.

Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.

Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:

 

 

Stage II: Market Data Analysis and Statistical Model

Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.

Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.

The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.

The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and  Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.

Data Triangulation & Validation:

Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.

We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.

 

 

Stage III: Interpretation and Presentation

Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)

  • Establishing market drivers and trends
  • Analyzing the regulatory landscape to understand future growth
  • Market Segment based analysis to obtain revenue/volume
  • ​Analyzing current needs and determining penetration to estimate the market

Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.

Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.

Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.

The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


This report addresses

  • Intelligent insights to take informed business decisions
  • Qualitative, acute and result oriented market analysis
  • Market size and forecasts from 2022 to 2030
  • Opportunities for expansion and in-depth market analysis
  • Segmentation and regional revenue forecasts
  • Analysis of the market share and competitive landscape
  • Strategic Recommendations to chart future course of action
  • Comprehensive Market Research Report in PDF and PPT formats

Need more?

  • Ask our analyst how this study was put together to learn more
  • Discuss additional requirements as part of the free customisation
  • Add more countries or regions to the scope 
  • Get answers to specific business questions 
  • Develop the business case to launch the product
  • Find out how this report may influence your business revenue
Last updated on: 08 December 2023
Updated by: Vidhi Upadhyay

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up